Alzheimer’s disease (AD) is characterized by progressive loss of cognitive abilities. Glutamate being the major excitatory neurotransmitter in mammalian brain, regulates various cognitive functions. Reports suggesting compromised cerebral glutamate homeostasis in AD indicates the potential of glutamate mapping in early diagnosis of AD. In the current study, we have used glutamate weighted Chemical Exchange Saturation Transfer (GluCEST) MRI to investigate changes in cerebral glutamate in 6-month-old APPNL-F/NL-F mouse model of AD. Our findings suggest reductions in the levels of cortical and hippocampal glutamate in APPNL-F/NL-F mice. A longitudinal study is ongoing to understand the pattern of perturbation with disease progression.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords